WHO Raises Alert Over Critical Lack of Obesity Injections
Fewer than one in 10 people eligible to benefit from weight-loss injections such as Wegovy have access to them, states the global health agency as it publishes its first recommendations on the therapies.
With over a billion people worldwide now living with obesity, it is urging increased and just access to GLP-1 medication.
According to estimates, over two billion could be living with obesity by 2030 if no action is taken.
"The new guidelines recognises that obesity is a chronic disease that can be addressed with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are key obstacles to widespread availability to the jabs that can assist patients in reducing substantial weight, says the body.
Skinny Jab Scarcity
Even in the present most optimistic case, the production of these medications might only reach about 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation urges governments and firms to widen availability, via approaches including patent sharing.
Exclusive production rights on semaglutide – the main component of a leading brand – is due to expire in several nations in 2026.
How Obesity Jabs Operate
The injections mimick a biological compound to delay gastric emptying, suppress the appetite and boost satiety so individuals eat less.
Patients typically begin shedding pounds in the initial weeks of beginning the weekly injections.
Studies indicates patients may see weight return a year later of discontinuing the medication, as their usual food cravings resume.
Being carrying excess weight increases your chance for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity concerns individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
